August 16, 2021Open Access

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

Key Points

Key points are not available for this paper at this time.

Abstract

Vedolizumab SC is an effective and safe maintenance therapy in patients with CD who responded to two infusions of vedolizumab intravenous induction therapy.

Read Full Paperexternally

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Vermeire et al. (Mon,) studied this question.

synapsesocial.com/papers/69db2bcd5b363cdf1c83585a https://doi.org/https://doi.org/10.1093/ecco-jcc/jjab133

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Understanding the Hawthorne effect2015 · 808 citations
2How do patients with inflammatory bowel disease want their biological therapy administered?2010 · 127 citations
3A Cross-sectional Survey on the Preference of Patients with Rheumatoid Arthritis for Route of Administration of Disease-Modifying Anti-Rheumatic Drugs: Oral Target-Specific Versus Parenteral Biologic.2020 · 15 citations
4Long-term Efficacy of Vedolizumab for Crohn’s Disease2016 · 215 citations
5Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis2019 · 318 citations

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper